

Amendments to the Claims

1-10 (Cancelled)

11. (Withdrawn)


12. (Withdrawn)

13. (Cancelled)

14. (Cancelled)

15-22. (Cancelled)

23. (New) A compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, or 2;

q represents an integer being 0, 1, or 2;

X represents O, S, NR^3 or a direct bond;

R^1 represents hydrogen, hydroxy, halo, amino, C_{1-6} alkyl, C_{1-6} alkyloxy or mono- or

di(C_{1-4} alkyl)amino C_{1-4} alkylamino; in particular, hydrogen, methyl and hydroxy;

R^2 represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2 , R^{11} and C_{1-4} alkyl optionally substituted with Het^2 or R^{11} ;

each R^4 independently represents C_{1-6} alkyl, halo, polyhalo C_{1-6} alkyl or C_{1-6} alkyloxy;

each R⁵ independently represents C₁₋₆alkyl, halo or C₁₋₆alkyloxy;

each R⁶ independently represents C₁₋₆alkylsulfonyl, aminosulfonyl or phenylC₁₋₄alkylsulfonyl;

each R⁷ and each R⁸ are independently selected from hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl,

dihydroxyC₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, mono- or

di(C₁₋₄alkyl)aminoC₁₋₄alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C₃₋₇cycloalkyl,

pyridinylC₁₋₄alkyl, Het³ and R⁶;

R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl,

C₁₋₄alkylcarbonyloxyC₁₋₄alkylcarbonyl, hydroxyC₁₋₄alkylcarbonyl,

C₁₋₄alkyloxyC₁₋₄alkylcarbonyl, Het³aminothiocarbonyl and R⁶;

each R¹¹ independently being selected from hydroxy, mercapto, cyano, nitro, halo,

trihalomethyl, C₁₋₄alkyloxy, carboxyl, C₁₋₄alkyloxyC₁₋₄alkylcarbonyl, trihaloC₁₋₄alkylsulfonyloxy,

R⁶, NR⁷R⁸, C(=O)NR⁷R⁸, aryl, aryloxy, arylcarbonyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy,

phthalimide-2-yl, Het³ and C(=O)Het³;

R¹² and R¹³ are each independently selected from hydrogen and C₁₋₄alkyl;

aryl represents phenyl optionally substituted with one, two or three substituents each

independently selected from nitro, azido, halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy,

polyhaloC₁₋₄alkyl, NR⁹R¹⁰, R⁶, phenyl, Het³ and C₁₋₄alkyl substituted with NR⁹R¹⁰;

Het¹ represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl,

furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl,

pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl,

1H-pyrazolo-[3,4-d]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl,

imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be

substituted with one, or where possible, two or three substituents each independently

selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹;

Het² represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each

independently may optionally be substituted with C₁₋₄alkyl;

Het³ represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein

said monocyclic heterocycles each independently may optionally be substituted with, where

possible, one, two or three substituents each independently selected from C₁₋₄alkyl, C₁₋

4alkyloxy, C₁₋₄alkyloxyC₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl, phenylC₁₋₄alkyl, piperidinyl, NR¹²R¹³

and C₁₋₄alkyl substituted with NR¹²R¹³.


24. (New) A compound according to claim 23 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

25. (New) A compound according to claim 24 wherein q is 1 or 2 and one R⁴ substituent is in the 4 position; and p is 1 or 2 and the one or two R⁵ substituents are in the ortho position relative to the central carbon atom.


26. (New) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 23.

27. (New) A process for preparing a composition as claimed in claim 26, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 23.

28. (New) A process for preparing a compound as claimed in claim 23, comprising
a) reacting an intermediate of formula (II) wherein W¹ is a suitable leaving group with an appropriate reagent of formula (III) optionally in a reaction-inert solvent and in the presence of a base;




wherein R¹, R², R⁴, X and q are as defined in claim 23, and D represents




wherein R⁵ and p are defined as in claim 23;

b) eliminating group E, wherein group E represents an appropriate electron attracting group, of a triazinedione of formula (V)




wherein R^1 , R^2 , R^4 , R^5 , X and q are as defined in claim 23;

c) reacting a ketone of formula (X) with an intermediate of formula (III-a) in the presence of a base and in a reaction-inert solvent; thus obtaining a compound of formula (I-a-2);




wherein R^2 , R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);

d) converting a compound of formula (I-a-2) to a compound of formula (I-a-3) using art-known group transformation reactions,




wherein R^2 , R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);

e) converting a compound of formula (I-a-2) to a compound of formula (I-a-4) using art-known group transformation reactions,




wherein R^2 , R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);

f) converting a compound of formula (I-a-4) to a compound of formula (I-a-5) using art-known group transformation reactions,



wherein R^2 , R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);


g) reacting an intermediate of formula (XII) wherein W^4 is a suitable leaving group with an intermediate of formula (III) optionally in the presence of a suitable base; thus obtaining a compounds of formula (I-b);



wherein R^2 , R^4 , X and q are as defined in claim 23 and D is defined as in paragraph


(a);

h) reacting an intermediate of formula (XIV) with an intermediate of formula (XV) wherein W^3 is a suitable leaving group, in the presence of a suitable base and optionally in the presence of a reaction-inert solvent; thus obtaining a compound of formula (I-c);




wherein R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);

i) cyclizing an intermediate of formula (XX) wherein Y is O, S or NR^3 , to a compound of formula (I-d-1), in the presence of a suitable solvent at an elevated temperature;




wherein R represents R^{11} as defined in claim 23, R^1 , R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);

j) cyclizing an intermediate of formula (XXI) to a compound of formula (I-d-2) in a reaction-inert solvent at an elevated temperature,




wherein R represents R¹¹ as defined in claim 23, R¹, R⁴ and q are as defined in claim 23 and D is defined as in paragraph (a);

k) cyclizing an intermediate of formula (XXII) wherein Y is O, S or NR³, to a compound of formula (I-d-3), in a suitable solvent,




wherein R represents R¹¹ as defined in claim 23, R¹, R⁴ and q are as defined in claim 23 and D is defined as in paragraph (a);

l) cyclizing an intermediate of formula (XXIII) wherein Y is O, S or NR³, to a compound of formula (I-d-4), in a reaction-inert solvent and in the presence of an acid,




wherein the R substituted amino residue NR⁷R⁸ as defined in claim 23, R¹, R⁴ and q are as defined in claim 23 and D is defined as in paragraph (a);

m) cyclizing an intermediate of formula (XXIII) wherein Y is O, S or NR³, to a compound of formula (I-d-5), in a reaction-inert solvent and in the presence of an acid,




wherein R represents R¹¹ as defined in claim 23, R¹, R⁴ and q are as defined in claim 23 and D is defined as in paragraph (a);

n) reacting an intermediate of formula (XXIV) with an intermediate of formula (XXV) wherein Y is O, S or NR³, and W⁵ is a suitable leaving group; thus forming a compound of formula (I-d-6) in a reaction-inert solvent and in the presence of a base,




wherein R represents R¹¹ as defined in claim 23, R¹, R⁴ and q are as defined in claim 23 and D is defined as in paragraph (a);

o) reacting an intermediate of formula (XXVI) with an intermediate of formula (XXVII) wherein W⁶ is a suitable leaving group; thus forming a compound of formula (I-d-7), in a reaction-inert solvent and in the presence of an acid;



wherein R represents R¹¹ as defined in claim 23, R¹, R⁴ and q are as defined in claim 23 and D is defined as in paragraph (a);

p) reacting an intermediate of formula (XXXIII) with a thioamide of formula (XXXIV); thus forming a compound of formula (I-d-9) in a reaction-inert solvent at an elevated temperature;



wherein R represents R^{11} as defined in claim 23, R^1 , R^4 and q are as defined in claim 23 and D is defined as in paragraph (a);

and if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and also, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.

29. (New) A method for treating eosinophil-dependent inflammatory diseases in a warm-blooded animal in need thereof comprising administering to the warm-blooded animal an effective amount of a compound of Claim 23.

30. (New) The method of Claim 29, wherein the eosinophil-dependent inflammatory disease is selected from bronchial asthma, atopic dermatitis, allergic rhinitis or allergic conjunctivitis.